5th World Congress on Cancer Therapy
Sree Chitra Tirunal Institute for Medical Sciences and Technology, India
Title: Development and preclinical testing of protein-based curcumin delivery forms for control of cancer
Biography: Lissy Krishnan
This lecture will address properties of plasma protein-based drug delivery systems with immense potential as anticancer agent. Curcumin (diferuloylmethane) is a well proven anti-infl ammatory, anti-oxidant and anticancer natural molecule with little clinical outcome due to poor aqueous solubility and lack of bioavailability. Diff erent approaches being attempted for eff ective delivery of this valuable drug at the aff ected site have not shown better clinical outcome. Recently, two drug delivery forms were developed using human proteins as drug carrier for: (i) local sustained release from fi brin matrix; (ii) systemic application as highly soluble Curcumin-albumin (Curc-Alb) conjugate. Potency of the curcumin released from fi brin and Curc-alb on in vitro proliferation and apoptosis were demonstrated using cancer cell lines, in vitro. Subsequently safe and effi cient use of the delivery systems for tumor prevention and reduction was demonstrated using Dalton’s lymphoma ascites (DLA) model in rats. Curcumin was non lethal/toxic when high acute dose was administered using both delivery forms. Sub-acute dose did not alter; liver/kidney functions as compared to normal controls. Drug administration aimed both tumor reduction and prevention of metastasis and in both the protocols it was comparable to the eff ect of standard drug doxorubicin. Remarkable reduction in tumor volume, tumor cell number and increase in mean survival time as compared to untreated tumor controls was observed and was similar to the action of standard drug. So the curcumin delivered in both forms appears safe and eff ective for human use. Th e potential of the drug and delivery systems for limited clinical trials will be discussed.